BENCH TO CLINIC IN CONCURRENT CHEMORADIATION THERAPY

同步放化疗中的临床工作台

• 批准号: 6649276
• 负责人: HAK CHOY
• 金额: $ 10.61万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-30 至 2004-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6649276
• 关键词: DNA topoisomerases; antineoplastics; carboplatin; clinical research; clinical trial phase I; clinical trial phase II; combination cancer therapy; cytotoxicity; drug screening /evaluation; enzyme inhibitors; head /neck neoplasm; human subject; human therapy evaluation; irinotecan; laboratory mouse; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplastic cell; nonhuman therapy evaluation; nonsmall cell lung cancer; paclitaxel; patient oriented research; pharmacokinetics; radiation dosage; radiosensitizer; topotecan

The principal investigator has a significant record in research that is both patient-oriented, and translational. A unique and important aspect of his career for the purposes of the K-24 Research Career Award is his continuous involvement with specific interventions beginning with pre-clinical work in the laboratory, and carrying through phases I, II, and III clinical trials. His primary research interest is in the study and development of new therapeutic agents that enhance the cell killing effects of radiation in cancer treatment. Current research projects involve bench studies of 4 agents that enhance the effects of radiation therapy-docetaxel, RFS-2000, RSR-13, and JM-216, all of which act by distinctly different mechanisms. Some studies involve a single agent and radiation therapy, while others involve a combination of chemotherapeutic agents together with radiation. Clinical studies involve three phase I studies of concurrent radiosensitizing agents and radiation therapy - docetaxel, irinotecan, and JM-216. One phase II study involves the allosteric modifier, RSR-13 and radiation therapy. All studies have been continuously supported through private pharmaceutical firm funding, and will continue to be so for the foreseeable future. He has initiated and stimulated a clinical research program in radiation oncology at the Vanderbilt Cancer Center, and was named Director of Clinical Research. Mentoring activities have been a consistent theme throughout his career, both at Brown University and at Vanderbilt. He initiated a fellowship program in radiation oncology clinical research using private funding, and has recruited 3 fellows into the program. Current mentoring activities involve 3 new faculty in the Vanderbilt Cancer Center. He initiated a mixed specialty symposium conference in concomitant chemoradiotherapy, which is continuing as a biennial conference. The K-24 Research Career Award will give the PI an opportunity to concentrate efforts on currently active clinical research projects, moving bench studies through to clinical trials, completing currently active clinical trials, and initiating studies on promising new agents.

主要研究者在以患者为导向的研究和翻译方面有着重要的记录。 他的职业生涯的一个独特和重要的方面，为K-24研究职业奖的目的是他不断参与具体的干预措施，从实验室的临床前工作开始，并通过I期，II期和III期临床试验进行。 他的主要研究兴趣是研究和开发新的治疗药物，以增强癌症治疗中辐射的细胞杀伤作用。 目前的研究项目涉及4种药物的实验室研究，这些药物可以增强放射治疗的效果-多西他赛，RFS-2000，RSR-13和JM-216，所有这些药物都通过明显不同的机制起作用。 一些研究涉及单一药剂和放射疗法，而另一些研究涉及化疗剂与放射的组合。临床研究涉及三项放射增敏剂和放射治疗并行的I期研究-多西他赛、伊立替康和JM-216。 一项II期研究涉及变构调节剂RSR-13和放射治疗。 所有研究都得到了私营制药公司资金的持续支持，在可预见的未来将继续如此。他在范德比尔特癌症中心发起并推动了一项放射肿瘤学的临床研究计划，并被任命为临床研究主任。 导师活动一直是一个一贯的主题，在他的职业生涯中，无论是在布朗大学和范德比尔特。 他利用私人资金发起了一项放射肿瘤学临床研究奖学金计划，并招募了3名研究员参加该计划。 目前的指导活动涉及范德比尔特癌症中心的3名新教师。他发起了一个混合专业研讨会会议，在伴随放化疗，这是继续作为一个两年一度的会议。K-24研究职业奖将为PI提供一个机会，使其专注于当前活跃的临床研究项目，将实验室研究转移到临床试验，完成当前活跃的临床试验，并启动有前途的新药研究。

项目成果

A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.

• 发表时间: 2001-10
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: H. Pyo;H. Choy;G. Amorino;Jae Sung Kim;Q. Cao;Sherri K. Hercules;R. Dubois

Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study.

多机构研究中二维数据重建三维剂量的剂量学不确定性。

• DOI: 10.1120/jacmp.v5i4.2012
• 发表时间: 2004
• 期刊: Journal of applied clinical medical physics
• 影响因子: 2.1
• 作者: Weinberg,Rebecca;Kaurin,DarrylGL;Choy,Hak;CurranJr,WalterJ;MacRae,Robert;Kim,JaeSung;Kim,Jaechul;Tucker,SusanL;Bonomi,PhilipD;Belani,Chandra;Starkschall,George
• 通讯作者: Starkschall,George

Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.

• DOI: 10.1016/s0167-8140(01)00465-0
• 发表时间: 2002
• 期刊: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
• 作者: J. Kim;G. Amorino;H. Pyo;Q. Cao;H. Choy

COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.

COX-2 抑制剂作为放射增强剂：治疗肺癌的新策略。

• DOI: 10.1097/01.coc.0000074161.92815.93
• 发表时间: 2003
• 期刊: American journal of clinical oncology : the official publication of the American Radium Society.
• 作者: Saha,Debabrata;Pyo,Hongryull;Choy,Hak
• 通讯作者: Choy,Hak